



COMPARISON OF THROMBOXANE A₂
IN NORMAL AND DIABETIC BLOOD PLATELETS
BY SUPERFUSION BIOASSAY

BY

SUPATTA TEMBOONKIAT

A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF
THE REQUIREMENTS FOR THE DEGREE OF
MASTER OF SCIENCE
(PHARMACOLOGY)

IN THE
FACULTY OF GRADUATE STUDIES
OF
MAHIDOL UNIVERSITY

1985

With compliments
of

ศาสตราจารย์ ดร. วิมล วัฒนศิริ

TH
59590
1985
c.2



ABSTRACT

The superfusion bioassay of relative TXA_2 in blood platelets of normal subjects, diabetic patients with and without DR was studied. The patients with DR were on aspirin for treatment of their retinopathy. Platelet aggregation was estimated by Born's method. Of 18 normal subjects, two of them were disaggregating type, four were hypo-normal type, other seven were normal type and the rest were hyperaggregating type of platelet activity. In 22 diabetics without aspirin treatment, nine had platelet disaggregating activity; the other eight, three and one were normal, hyper-normal and hyperaggregating activity, respectively. The estimation of platelet aggregation of one subject in this group was impossible due to the turbidity of her PRP. Eight of 10 diabetics with aspirin-intake showed platelet disaggregating type. Each of the two left was hypo-normal and normal type, respectively.

The washed platelet suspension in the Krebs solution without calcium was prepared from PRP. Bioassay of TXA_2 in thrombin-treated platelet suspension was carried out using the rabbit aorta superfusion technique at $37^\circ C$. Estimated TXA_2 level was a relative value. The diabetics without aspirin treatment had the highest concentrations of TXA_2 with the mean \pm S.D. equal to 2.27 ± 1.69 , while the estimated TXA_2 in normal subjects was assumed to be 1.00. The diabetics with aspirin-intake had the lowest concentrations of TXA_2 with the mean \pm S.D. of 0.66 ± 0.40 . The relative TXA_2 levels of the normal and diabetic with aspirin-intake groups were significantly different from that of the diabetic without aspirin group ($p < 0.001$). The difference of the relative

TXA₂ concentrations in the normal and diabetic with aspirin-intake groups was also statistically significant ($p < 0.05$). This indicated that DM tended to have higher concentrations of TXA₂ than normal and this might be a cause of several vascular complications in DM. In addition, aspirin does reduce the TXA₂ concentrations. Treatment or prevention of the diabetic complications by the PG inhibitor seems to be rational. However, further studies in this field are needed for this conclusion.

After washing procedure, the loss of platelets occurred. Therefore, it was necessary to concentrate the washed platelets to obtain the sufficient TXA₂ activity. The platelet yield from our washing procedure was about 50%.

There was a report indicated the unstability of TXA₂ that its half-life was 30 sec at 37°C. We, therefore, determined the degradation-time of TXA₂ by the superfusion technique. The result was that TXA₂ contracting activity had still been detectable up to 6 min.

The study of TXA₂ will be the basis of searching for new drugs that have abolished the TXA₂ activity or synthesis. They may be useful in treatment or prevention of the pathology caused by the excessive amounts of TXA₂.